行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

4.780
-0.110
-2.25%
已收盘, 16:39 08/06 EDT
开盘
4.890
昨收
4.890
最高
4.990
最低
4.750
成交量
20.05万
成交额
--
52周最高
5.36
52周最低
0.4900
市值
1.12亿
市盈率(TTM)
-6.8787
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NAVB价格均价为5.00,最高价位6.00,最低价为4.000。

EPS

NAVB 新闻

更多
Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/25 08:50
Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock?
Zacks · 06/17 14:43
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
GlobeNewswire · 06/15 13:00
Navidea Biopharma Reports Full Enrollment In Ongoing Phase 2b Trial OF Tc99m Tilmanocept In Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce
Benzinga · 06/15 12:19
Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series
GlobeNewswire · 06/09 12:30
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress
GlobeNewswire · 06/03 12:30
Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At The European League Against Rheumatism (EULAR) Congress
DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision
Benzinga · 06/03 11:33
Company News for May 26, 2020
Zacks · 05/26 15:11

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

NAVB 简况

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.
展开

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NAVB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NAVB股票基本功能。